THE GLOBAL REGENERATIVE MEDICINE MARKET SIZE WAS VALUED AT USD 4.68 BILLION IN 2020 AND IS EXPECTED TO REACH USD 27.08 BILLION BY 2026, AT A CAGR OF 34% DURING 2021-2026

Regenerative Medicine Market Size and Share & Trends Analysis Report by Application (Oncology, Genetic Disorders, Dermatology, Musculoskeletal, and Other), Product Type (Gene Therapies, Cell Therapies, and Tissue-Engineered), End-Users (Hospitals, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Other End-Users), Geography (North America, Europe, APAC, Latin America, and Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2021–2026.

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

284 Pages

84 Tables

159 Charts

5 Regions

18 Countries

39 Companies

4 Market Segment

REGENERATIVE MEDICINE MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 27.08 BILLION (2026)
CAGR 34% (2021–2026)
Base Year 2020
Forecast Year 2021–2026
Market Segments Application (Oncology, Genetic Disorders, Dermatology, Musculoskeletal, and Other), Product Type (Gene Therapies, Cell Therapies, and Tissue-Engineered), End-users (Hospitals, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, Germany, France, UK, Italy, Spain, Japan, China, Australia, South Korea, India, Brazil, Mexico, Turkey, Saudi Arabia, South Africa, and UAE

REGENERATIVE MEDICINE INDUSTRY INSIGHTS

The global regenerative medicine market size was valued at USD 4.68 billion in 2020 and is estimated to reach USD 27.08 billion by 2026, growing at a cumulative average growth rate (CAGR) of 30% during the forecast period. The increasing prevalence of cancer and genetic disorders is popularizing the regenerative medicine trends across the globe.

Increased R&D investments by pharmaceutical companies will drive the demand for regenerative medicines. Europe plays a significant role in supporting the development and authorization of these products for several genetic and rare disorders. Increased funding via several venture capitalists and governments, and private institutions contribute significantly to the global regenerative medicine market growth. The regenerative medicine market is growing at a significant rate in the APAC region and is expected to increase during the forecast period. The most prominent factor responsible for the growth is the increased funding in the region for the development of health care. 

The increased prevalence of diseases such as cardiovascular diseases and diabetes can drive cell and gene therapy and tissue-engineered products. With the rise in thermal burns, occupational burn accidents, and chronic wounds, regenerative medicine products will experience steady growth. Novartis and Gilead Sciences are the key companies offering various therapies to treat cancer, genetic, and rare disorders. Many key players in the market have developed innovative therapies in the field of RM. For instance, in February 2021, Bristol-Myers Squibb received the US FDA approval for its product Lisocel, which is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

SNIPPETS

  • Cell and gene therapy is rapidly emerging as the most promising part of regenerative medicines due to the rising incidences of cancer.
  • Mergers and Acquisitions are the latest trends in the industry. The key vendors are acquiring the existing highly successful cell and gene therapy companies with huge amounts. The overall merger and acquisition activities are worth up to USD 33 billion in the regenerative medicine industry.
  • South Korea is one of the leading regions in APAC, with significant innovation and development in cell-based therapy, specifically using stem cell therapies. APAC has the most favorable regulatory environment so that the process of clinical trials can be conducted smoothly. 
  • The European Union focuses on the largest innovation and research program with USD 95 billion funding over seven years from 2007–2020.

REGENERATIVE MEDICINE INDUSTRY OPPORTUNITIES AND GROWTH FACTORS

  • A strong pipeline portfolio by numerous companies will boost the market growth in the long term. In 2021, almost 1200 products in the global regenerative medicine pipeline are in different phases of clinical trials. 
  • The faster regulatory approvals for the cell and gene therapy products, especially from the US and European regulatory authorities, provide huge opportunities to penetrate the market faster.
  • Rapid product developments and innovative product launch in the industry every year with smooth and favorable approvals is boosting the opportunities in the industry.

REGENERATIVE MEDICINE MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Application
  • Products
  • End-users
  • Geography

INSIGHTS BY APPLICATION

The oncology segment expects to occupy absolute growth of over USD 14 billion by 2026

Oncology constitutes the largest portion of the global regenerative medicine market share. The oncology segment is expected to grow at a CAGR of 43.75%. The development of curative therapies by CAR-T and cell and gene therapies is widely popularized in the oncology therapeutic area. According to the Alliance for Regenerative Medicine, the response rate among patients is 90% for recently approved CAR T-cell therapy Tecartus by Kite Pharma, a Gilead Services company, for the treatment of relapsed/refractory mantle cell lymphoma.

The genetic disorder segment will witness an incremental growth of over USD 8 billion by 2026. The rapid increase in genetic and serious life-threatening rare disorders is one of the important factors that drive the market. In addition, the increasing burden of genetic diseases is growing across the globe, thereby influencing industry growth.

INSIGHTS BY PRODUCT

The gene therapy segment is anticipated to retain market dominance during the forecast period.

Consistent innovations in gene therapies due to the increased number of clinical trials and pipeline products are driving the growth prospects. Hence, the increased inflow of funding for the development of gene therapy is one of the driving factors for the sector growth cell therapy is the major revenue contributor. The increasing prevalence of diabetes and foot ulcers is the primary factor contributing to the growth of tissue-engineered products. The tissue-engineered product segment to grow at a CAGR of 8% by 2026.

Increased funding from government bodies and venture capitalists leads to the development of advanced and innovative cell therapies. The rising awareness and expansion of reimbursement schemes in the emerging market will generate lucrative growth opportunities for cell therapy products.

INSIGHTS BY END-USERS

Hospitals are the fastest-growing end-user segment.

Hospitals are likely to remain a dominant revenue contributor to the global regenerative medicine market. Around 50% of therapeutic surgeries performed in the US annually, including cardiovascular and musculoskeletal, occur in hospitals. Cancer care centers are likely to witness an incremental growth of approx. USD 10 billion by 2026. As cancer is the second leading cause of death across the globe, which is responsible for approx. 10 million deaths annually, the scope of cancer centers is growing. Key vendors are focusing more on cancer care centers than hospitals to promote their products. As the cancer centers are being covered under reimbursement schemes, the growth of these facilities is likely to increase during the forecast period.

INSIGHTS BY GEOGRAPHY

In North America, the acceptance of regenerative medicine is relatively higher than in other developed countries. North America to accounts for the largest market share of the global regenerative medicine market. The growth can be primarily attributed to the increasing population with different types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukemia in the North American region. Furthermore, North America consists of the highest number of regenerative medicine companies, which is adding to the market growth in the region. Europe has highly developed manufacturing facilities, which is driving the market growth in the European region. Most vendors in Europe depend on external sources for expansion and R&D activities.

COMPETITIVE LANDSCAPE

Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the key vendors in the global regenerative medicine market. Global key players dominate the market shares due to wide distribution networks, innovative product launches, and broad product offerings. Companies are focusing on product innovations and strengthening their distribution channel to expand market presence globally. The market has developed innovative therapies in the field. Small players are collaborating with prominent players to gain a competitive advantage in the market.

The global regenerative medicine market research report includes in-depth coverage of industry analysis with revenue and forecast insights for the following segments:

Segmentation by Application

  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others

Segmentation by Product

  • Gene Therapies
  • Cell Therapies
  • Tissue-Engineered Therapies

Segmentation by End-Users

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • ASCs
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • Australia
    • South Korea
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • UAE

Frequently Asked Questions

Global Regenerative medicine market size is to likely to reach USD 27 billion by 2026, growing at a CAGR of over 30% during the forecast period.
Oncology, genetic disorders, and musculoskeletal disorders are the critical applications of the product.
Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the major vendors in the market.
The gene therapy segment is likely to account for the largest industry share.
North America is likely to hold the largest share by 2026.
The COVID-19 pandemic disrupted the supply chain of raw materials required to commercialize gene cell therapy and tissue-engineered products.
Download Free Sample

The regenerative medicine market size to grow at a CAGR of around 30% during the period 2020-2026.

The following factors are likely to contribute to the growth of the regenerative medicine market during the forecast period:

  • Increase in the Patient Pool with Acute, Chronic, and Genetic Disorders
  • Strong Pipeline Portfolio of Regenerative Medicine Companies
  • Implementation of Advanced tissue-engineering Therapies Technology
  • Faster Regulatory approvals

Base Year: 2020

Forecast year: 2019-2026

The report considers the present scenario of the regenerative medicine market and its market dynamics for 2019−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market. 

Key Vendors

  • Novartis
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Gilead Sciences
  • Amgen
  • Organogenesis
  • Bristol Myers Squibb
  • Vericle
  • Osiris Therapeutics

 

Other Prominent Vendors

  • Anges
    • Business Overviews
    • Products Offerings
  • Orchard Therapeutics
  • Orthofix
  • Integra Life Science
  • MiMedx
  • bluebird bio
  • Mesoblast
  • Avita Medical
  • Takeda Pharmaceuticals
  • Medipost
  • TissueTech
  • Misonix
  • J-TEC
  • Stempeutics
  • CO.DON
  • GC Pharma
  • Orthocell
  • Tego Science
  • Nipro
  • S-BIOMEDIC
  • APAC Biotech
  • Bio Solution
  • Chiesi Farmaceutici
  • Collplant
  • Corestem
  • Human Stem Cell Institute
  • JCR Pharmaceuticals
  • JW CreaGene
  • Nuvasive
  • Sibiono GeneTech
  • Shanghai Sunway Biotech
  • Terumo

Segmentation by Application

  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others

Segmentation by Product

  • Gene Therapies
  • Cell Therapies
  • Tissue-Engineered Therapies

Segmentation by End-Users

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • ASCs
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • Australia
    • South Korea
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • UAE

1            Research Methodology

2            Research Objectives

3            Research Process

 

4            Scope & Coverage

4.1        Market Definition

4.1.1     Inclusions

4.1.2     Exclusions

4.2        Base Year

4.3        Scope of The Study

4.3.1     Market Segmentation By Application

4.3.2     Market Segmentation By Product

4.3.3     Market Segmentation By End-users

4.3.4     Market Segmentation by Geography

 

5            Report Assumptions & Caveats

5.1        Key Caveats

5.2        Currency Conversion

5.3        Market Derivation

 

6            Market at a Glance

7            Introduction

7.1        Overview

 

8            Market Opportunities & Trends

8.1        Latest Advances In Tissue-Engineering Therapies

8.2        Robust Product Pipeline Of Regenerative Medicine Companies

8.3        Strategic Acquisitions By Regenerative Medicine Companies

 

9            Market Growth Enablers

9.1        Increase In Acute, Chronic, & Genetic Disorders

9.2        Increasing Demand For Car T-Cell Therapies

9.3        Faster Regulatory Approvals & Special Designations Of Rm Products

 

10         Market Restraints

10.1      Manufacturing, Operational, & Ethical Challenges

10.2      High Cost of Regenerative Therapies

10.3      Outbreak of The COVID-19 Pandemic

 

11         Market Landscape

11.1      Market Overview

11.2      Market Size & Forecast

11.3      Five Forces Analysis

11.3.1   Threat of New Entrants

11.3.2   Bargaining Power of Suppliers

11.3.3   Bargaining Power of Buyers

11.3.4   Threat of Substitutes

11.3.5   Competitive Rivalry

 

12         Application

12.1      Market Snapshot & Growth Engine

12.2      Market Overview

12.3      Dermatology

12.3.1   Market Overview

12.3.2   Market Size & Forecast

12.4      Musculoskeletal

12.4.1   Market Overview

12.4.2   Market Size & Forecast

12.5      Oncology

12.5.1   Market Overview

12.5.2   Market Size & Forecast

12.6      Genetic Disorders

12.6.1   Market Overview

12.6.2   Market Size & Forecast

12.7      Other Applications

12.7.1   Market Overview

12.7.2   Market Size & Forecast

 

13         Product

13.1      Market Snapshot & Growth Engine

13.2      Market Overview

13.3      Gene Therapy

13.3.1   Market Overview

13.3.2   Market Size & Forecast

13.4      Cell Therapy

13.4.1   Market Overview

13.4.2   Market Size & Forecast

13.5      Tissue-Engineering

13.5.1   Market Overview

13.5.2   Market Size & Forecast

 

14         End-Users

14.1      Market Snapshot & Growth Engine

14.2      Market Overview

14.3      Hospitals

14.3.1   Market Overview

14.3.2   Market Size & Forecast

14.4      Cancer Care Centers

14.4.1   Market Overview

14.4.2   Market Size & Forecast

14.5      Wound Care Centers

14.5.1   Market Overview

14.5.2   Market Size & Forecast

14.6      Ambulatory Surgical Centers

14.6.1   Market Overview

14.6.2   Market Size & Forecast

14.7      Others

14.7.1   Market Overview

14.7.2   Market Size & Forecast

 

15         Geography

15.1      Market Snapshot & Growth Engine

15.2      Geographic Overview

 

16         North America

16.1      Market Overview

16.2      Market Size & Forecast

16.3      Key Countries

16.3.1   US: Market Size & Forecast

16.3.2   Canada: Market Size & Forecast

 

17         Europe

17.1      Market Overview

17.2      Market Size & Forecast

17.3      Key Countries

17.3.1   Germany: Market Size & Forecast

17.3.2   France: Market Size & Forecast

17.3.3   UK: Market Size & Forecast

17.3.4   Italy: Market Size & Forecast

17.3.5   Spain: Market Size & Forecast

 

18         APAC

18.1      Market Overview

18.2      Market Size & Forecast

18.3      Key Countries

18.3.1   Japan: Market Size & Forecast

18.3.2   China: Market Size & Forecast

18.3.3   Australia: Market Size & Forecast

18.3.4   South Korea: Market Size & Forecast

18.3.5   India: Market Size & Forecast

 

19         Latin America

19.1      Market Overview

19.2      Market Size & Forecast

19.3      Key Countries

19.3.1   Brazil: Market Size & Forecast

19.3.2   Mexico: Market Size & Forecast

 

20         Middle East & Africa

20.1      Market Overview

20.2      Market Size & Forecast

20.3      Key Countries

20.3.1   Turkey: Market Size & Forecast

20.3.2   Saudi Arabia: Market Size & Forecast

20.3.3   South Africa: Market Size & Forecast

20.3.4   UAE: Market Size & Forecast

 

21         Competitive Landscape

21.1      Competition Overview

21.2      Market Share Analysis

21.2.1   Novartis

21.2.2   Gilead Sciences

21.2.3   Amgen

21.2.4   Dendreon

21.2.5   Organogenesis

21.2.6   Bristol-Myers Squibb

21.2.7   Vericel

21.2.8   Osiris Therapeutics

21.2.9   F. Hoffmann-La Roche

 

22         Key Company Profiles

22.1      Novartis

22.1.1   Business Overview

22.1.2   Product Offerings

22.1.3   Key Strategies

22.1.4   Key Strengths

22.1.5   Key Opportunities

22.2      Gilead Sciences

22.2.1   Business Overview

22.2.2   Product Offerings

22.2.3   Key Strategies

22.2.4   Key Strengths

22.2.5   Key Opportunities

22.3      Amgen

22.3.1   Business Overview

22.3.2   Product Offerings

22.3.3   Key Strategies

22.3.4   Key Strengths

22.3.5   Key Opportunities

22.4      Organogenesis

22.4.1   Business Overview

22.4.2   Product Offerings

22.4.3   Key Strategies

22.4.4   Key Strengths

22.4.5   Key Opportunities

22.5      Bristol-Myers Squibb

22.5.1   Business Overview

22.5.2   Product Offerings

22.5.3   Key Strategies

22.5.4   Key Strengths

22.5.5   Key Opportunities

22.6      Vericel

22.6.1   Business Overview

22.6.2   Product Offerings

22.6.3   Key Strategies

22.6.4   Key Strengths

22.6.5   Key Opportunities

22.7      Osiris Therapeutics

22.7.1   Business Overview

22.7.2   Product Offerings

22.7.3   Key Strategies

22.7.4   Key Strengths

22.7.5   Key Opportunities

 

23         Other Prominent Vendors

23.1      ANGES

23.1.1   Business Overview

23.1.2   Product Offerings

23.2      APAC Biotech

23.2.1   Business Overview

23.2.2   Product Offerings

23.3      Avita Medical

23.3.1   Business Overview

23.3.2   Product Offerings

23.4      Bio Solution

23.4.1   Business Overview

23.4.2   Product Offerings

23.5      bluebird bio

23.5.1   Business Overview

23.5.2   Product Offerings

23.6      Chiesi Farmaceutici

23.6.1   Business Overview

23.6.2   Product Offerings

23.7      CO.DON

23.7.1   Business Overview

23.7.2   Product Offerings

23.8      Collplant

23.8.1   Business Overview

23.8.2   Product Offerings

23.9      Corestem

23.9.1   Business Overview

23.10    GC Pharma

23.10.1 Business Overview

23.10.2 Product Offerings

23.11    Human Stem Cell Institute

23.11.1 Business Overview

23.11.2 Product Offerings

23.12    Integra Life Sciences

23.12.1 Business Overview

23.12.2 Product Offerings

23.13    JCR Pharmaceuticals

23.13.1 Business Overview

23.13.2 Product Offerings

23.14    J-TEC

23.14.1 Business Overview

23.14.2 Product Offerings

23.15    JW CreaGene

23.15.1 Business Overview

23.15.2 Product Offerings

23.16    MEDIPOST

23.16.1 Business Overview

23.16.2 Product Offerings

23.17    MiMedx

23.17.1 Business Overview

23.17.2 Product Offerings

23.18    Misonix

23.18.1 Business Overview

23.18.2 Product Offerings

23.19    Mesoblast

23.19.1 Business Overview

23.19.2 Product Offerings

23.20    Nipro

23.20.1 Business Overview

23.20.2 Product Offerings

23.21    Nuvasive

23.21.1 Business Overview

23.21.2 Product Offerings

23.22    Orchard Therapeutics

23.22.1 Business Overview

23.22.2 Product Offerings

23.23    Orthifix

23.23.1 Business Overview

23.23.2 Product Offerings

23.24    Orthocell

23.24.1 Business Overview

23.24.2 Product Offerings

23.25    S.BIOMEDICS

23.25.1 Business Overview

23.25.2 Product Offerings

23.26    Sibiono GeneTech

23.26.1 Business Overview

23.26.2 Product Offerings

23.27    Shanghai Sunway Biotech

23.27.1 Business Overview

23.27.2 Product Offerings

23.28    Stempeutics

23.28.1 Business Overview

23.28.2 Product Offerings

23.29    Takeda Pharmaceuticals

23.29.1 Business Overview

23.29.2 Product Offerings

23.30    Tego Science

23.30.1 Business Overview

23.30.2 Product Offerings

23.31    Terumo

23.31.1 Business Overview

23.31.2 Product Offerings

23.32    Tissuetech

23.32.1 Business Overview

23.32.2 Product Offerings

 

24         Report Summary

24.1      Key Takeaways

24.2      Strategic Recommendations

 

25         Quantitative Summary

25.1      Market By Geography

25.2      Market By Application

25.3      Market By Product

25.4      Market By End-User

26         Appendix

26.1      Abbreviations

             

             

 

List of Exhibits 

Exhibit 1             Segmentation of Global Regenerative Medicine Market

Exhibit 2             Market Size Calculation Approach 2020

Exhibit 3             Regenerative Medicine Total Global Financing 2017–2020 ($ billion)

Exhibit 4             Latest Advances in Tissue-engineering Therapies

Exhibit 5             Robust Product Pipeline of Regenerative Medicine Companies

Exhibit 6             Number of Regenerative Medicine Products in Different Therapeutic Areas in Various Phases of Clinical Trials

Exhibit 7             Strategic Acquisitions by Regenerative Medicine Companies

Exhibit 8             Increase in Acute, Chronic, & Genetic Disorders

Exhibit 9             Acute Lymphoblastic Leukemia Cases Worldwide 1990-2020

Exhibit 10           Region-wise Prevalence of Non-Hodgkin Lymphoma from 2015 to 2020

Exhibit 11           Increasing Demand for CAR T-cell and Gene Therapies

Exhibit 12           Number of CAR T-Cell Therapies in Clinical Trials (January 2018)

Exhibit 13           Major Vendors engaged in CAR T-Cell Therapies Development

Exhibit 14           Faster Regulatory Approvals & Special Designations of RM Products

Exhibit 15           Manufacturing, Operational, & Ethical Challenges

Exhibit 16           Manufacturing & Operational Challenges Associated with Regenerative Medicine Products for Vendors

Exhibit 17           High Cost of Regenerative Therapies

Exhibit 18           Cost of Select Marketed Cell & Gene Therapy Products (lacs)

Exhibit 19           Outbreak of the COVID-19 Pandemic

Exhibit 20           Global Regenerative Medicine Market 2020–2026 ($ million)

Exhibit 21           Global Regenerative Medicine Market by Product: 2020&2026 Percentage Share Comparison

Exhibit 22           Global Regenerative Medicine Market by Application: 2020& 2026 Percentage Share Comparison

Exhibit 23           Global Regenerative Medicine Market by End-users 2020& 2026 Percentage Share Comparison

Exhibit 24           Global Regenerative Medicine Market by Geography: 2020 & 2026 Percentage Share Comparison

Exhibit 25           Five Forces Analysis 2020

Exhibit 26           Incremental Growth by Application 2020 & 2026

Exhibit 27           Global Regenerative Medicine Market by Application

Exhibit 28           Global Regenerative Medicine Market by Application: Incremental growth

Exhibit 29           Global Regenerative Medicine Market by Application: Absolute Growth

Exhibit 30           Distribution of Wound Types in Various Hospitals and Wound Care Centres (%)

Exhibit 31           Global Regenerative Medicine Market by Dermatology Incremental Growth Vs Absolute Growth

Exhibit 32           Global Regenerative Medicine Market by Dermatology 2020–2026 ($ million)

Exhibit 33           Global Regenerative Medicine Market by Musculoskeletal Application: Incremental Growth Vs Absolute Growth

Exhibit 34           Global Regenerative Medicine Market by Musculoskeletal Application 2020–2026 ($ million)

Exhibit 35           New Types of Cancer Cases reported Worldwide (2020)

Exhibit 36           Number of Products in Clinical Trials in Oncology Application

Exhibit 37           Global Regenerative Medicine Market by Oncology Application: Incremental Growth Versus Absolute Growth

Exhibit 38           Global Regenerative Medicine Market by Oncology Application 2020–2026 ($ million)

Exhibit 39           Global Regenerative Medicine Market by Genetic Disorders: Incremental Growth Vs Absolute Growth

Exhibit 40           Global Regenerative Medicine Market by Genetic Disorders 2020–2026 ($ million)

Exhibit 41           Global Regenerative Medicine Market by Other Applications: Incremental Growth Vs Absolute Growth

Exhibit 42           Global Regenerative Medicine Market by Other Applications 2020–2026 ($ million)

Exhibit 43           Incremental Growth by Product 2020 & 2026

Exhibit 44           Global Regenerative Medicine Market by Product

Exhibit 45           Global Regenerative Medicine Market by Product – Incremental Growth

Exhibit 46           Global Regenerative Medicine Market by Product – Absolute Growth

Exhibit 47           Important Events in the Development of Gene Therapy

Exhibit 48           Global Funding for Development of Gene Therapy 2017–2020 ($ billion)

Exhibit 49           Global Regenerative Medicine Market by Gene Therapy Incremental Growth Vs Absolute Growth

Exhibit 50           Global Regenerative Medicine Market by Gene Therapy 2020–2026 ($ million)

Exhibit 51           Global Funding for Development of Cell Therapy 2017–2020 ($ billion)

Exhibit 52           Global Regenerative Medicine Market by Cell Therapy Incremental Growth Vs. Absolute Growth

Exhibit 53           Global Regenerative Market by Cell Therapy 2020–2026 ($ million)

Exhibit 54           Global Funding for Development of Tissue-engineering Products 2017–2020 (million)

Exhibit 55           Prevalence of Diabetic Foot Ulcers in Different Regions

Exhibit 56           Global Regenerative Medicine Market by Tissue-engineered Products: Incremental Growth Vs. Absolute Growth

Exhibit 57           Global Regenerative Medicine Market by Tissue-engineered Products 2020–2026 ($ million)

Exhibit 58           Incremental Growth by End-users 2020 & 2026

Exhibit 59           Global Regenerative Medicine Market by End-users

Exhibit 60           Global Regenerative Medicine by End-users– Incremental Growth

Exhibit 61           Global Regenerative Medicine by End-users– Absolute Growth

Exhibit 62           Global Regenerative Medicine Market by Hospitals Incremental Growth Vs Absolute Growth

Exhibit 63           Global Regenerative Medicine Market by Hospitals 2020–2026 ($ million)

Exhibit 64           Global Regenerative Medicine Market by Cancer Care Centers Incremental Growth Vs Absolute Growth

Exhibit 65           Global Regenerative Medicine Market by Cancer Care Centers 2020–2026 ($ million)

Exhibit 66           Global Regenerative Medicine Market by Wound Care Centers Incremental Growth Vs Absolute Growth

Exhibit 67           Global Regenerative Medicine Market by Wound Care Centers 2020–2026 ($ million)

Exhibit 68           Percentages of Specialties in Ambulatory Service Centers

Exhibit 69           Global Regenerative Medicine Market by Ambulatory Surgical Centers Incremental Growth Vs. Absolute Growth

Exhibit 70           Global Regenerative Medicine Market by Ambulatory Service Centers 2020–2026 ($ million)

Exhibit 71           Global Regenerative Medicine Market by Others: Incremental Growth Vs Absolute Growth

Exhibit 72           Global Regenerative Medicine Market by Others End-users 2020–2026 ($ million)

Exhibit 73           Incremental Growth by Geography 2019 & 2025

Exhibit 74           Global Regenerative Medicine Market by Geography

Exhibit 75           Global Regenerative Medicine by Geography– Incremental Growth

Exhibit 76           Global Regenerative Medicine by Geography – Absolute Growth

Exhibit 77           Regenerative Medicine Market in North America: Key countries ($ million)

Exhibit 78           New Cancer Cases Reported in North America 2020

Exhibit 79           Regenerative Medicine Market in North America: Incremental Growth & Absolute Growth Comparisons

Exhibit 80           Regenerative Medicine Market in North America 2020–2026 ($ million)

Exhibit 81           Incremental Growth in North America 2020 & 2026

Exhibit 82           Estimated Number of New Cancer Cases in US 2017–2021

Exhibit 83           Major Regenerative Medicine Companies R&D Investments in 2020 ($ million)

Exhibit 84           Regenerative Medicine Market in US 2020–2026 ($ million)

Exhibit 85           Estimated Number of New Cancer Cases in Canada in 2020

Exhibit 86           Regenerative Medicine Market in Canada 2020–2026 ($ million)

Exhibit 87           Reported Cancer Cases in Europe 1995 & 2020 (million)

Exhibit 88           Number of Products designated Under PRIME Designation in Several Therapeutic Areas by EMA (2021)

Exhibit 89           Regenerative Medicine Market in Europe 2020–2026 ($ million)

Exhibit 90           Incremental Growth in Europe 2020 & 2026

Exhibit 91           Number of New Types of Cancer Cases in Germany (2020)

Exhibit 92           New Types of Cancer Cases Detected in France (2020)

Exhibit 93           Regenerative Medicine Market in France 2020–2026 ($ million)

Exhibit 94           Estimated Number of People living with Cancer by 2030 (million)

Exhibit 95           Number of Different Types of Cancer Cases in UK (2020)

Exhibit 96           Regenerative Medicine Market in UK  2020–2026 ($ million)

Exhibit 97           Per Capita Healthcare Expenditure in Italy between 2016 and 2018 ($)

Exhibit 98           Number of Different Types of Cancer reported in Italy (2020)

Exhibit 99           Regenerative Medicine Market in Italy 2020–2026 ($ million)

Exhibit 100        Number of Different Types of Cancers Cases reported in Spain (2020)

Exhibit 101        Regenerative Medicine Market in Spain 2020–2026 ($ million)

Exhibit 102        Regenerative Medicine Market in APAC: Key Countries ($ million)

Exhibit 103        Number of New Cancer Cases reported in APAC (2020)

Exhibit 104        Annual Health Care Costs (direct & indirect) of CVDs in APAC ($ billion)

Exhibit 105        Regenerative Medicine Market in APAC 2020–2026 ($ million)

Exhibit 106        Incremental Growth in APAC 2020 & 2026

Exhibit 107        Number of New Cancer Cases reported in Japan (2020)

Exhibit 108        Regenerative Medicine Market in Japan 2020–2026 ($ million)

Exhibit 109        Number of new Types of Cancer Cases reported in China (2020)

Exhibit 110        Regenerative Medicine Market in China 2020–2026 ($ million)

Exhibit 111        Number of New Types of Cancer Cases reported in Australia (2020)

Exhibit 112        Regenerative Medicine Market in Australia 2020–2026 ($ million)

Exhibit 113        Number of New Types of Cancers in South Korea (2020)

Exhibit 114        Regenerative Medicine Market in South Korea 2020–2026 ($ million)

Exhibit 115        Number of New Types of Cancer Cases reported in India (2020)

Exhibit 116        Regenerative Medicine Market in India 2020–2026 ($ million)

Exhibit 117        Regenerative Medicine Market in Latin America: Incremental Growth & Absolute Growth Comparison

Exhibit 118        New Types of Cancer Cases reported in Latin America (2020)

Exhibit 119        Country-wise Cancer Cases Detected in Latin America (2020)

Exhibit 120        Regenerative Medicine Market in Latin America: Key Countries ($ million)

Exhibit 121        Regenerative Medicine Market in Latin America 2020–2026 ($ million)

Exhibit 122        Incremental Growth in Latin America 2020 & 2026

Exhibit 123        Number of New Types of Cancer Cases reported in Brazil (2020)

Exhibit 124        Regenerative Medicine Market in Brazil 2020–2026 ($ million)

Exhibit 125        Number of New Types of Cancer Cases reported in Mexico (2020)

Exhibit 126        Mexico Per Capita Health Expenditure during 2016–2018 ($)

Exhibit 127        Regenerative Medicine Market in Mexico 2020–2026 ($ million)

Exhibit 128        Cancer Cases in Different Countries of Middle East African Region in 2020

Exhibit 129        Regenerative Medicine Market in Middle East & Africa: Incremental Growth & Absolute Growth Comparison

Exhibit 130        Regenerative Medicine Market in Middle East & Africa: Key Countries ($ million)

Exhibit 131        Regenerative Medicine Market in Middle East & Africa 2020–2026 ($ million)

Exhibit 132        Incremental Growth in Middle East & Africa 2020 & 2026

Exhibit 133        Number of New Cancer Cases reported in Turkey (2020)

Exhibit 134        Regenerative Medicine Market in Turkey 2020–2026($ million)

Exhibit 135        Per Capita Healthcare Expenditure in Saudi Arabia 2016-2018 ($)

Exhibit 136        Number of New Types of Cancer Cases reported in Saudi Arabia (2020)

Exhibit 137        Regenerative Medicine Market in Saudi Arabia 2020–2026 ($ million)

Exhibit 138        Percentage of Incidence and Mortality Rates by of Cancer Types in South Africa

Exhibit 139        Regenerative Medicine Market in South Africa 2020–2026 ($ million)

Exhibit 140        Number of New Types of Cancer Cases reported in UAE (2020)

Exhibit 141        Regenerative Medicine Market in UAE 2020–2026 ($ million)

Exhibit 142        Novartis Revenue 2018–2020 ($ million)

Exhibit 143        Novartis R&D Expenditure 2018–2020 ($ million)

Exhibit 144        Novartis Segments Revenue 2018–2020 ($ million)

Exhibit 145        Novartis Sales Breakdown by Region 2108–2020 ($ million)

Exhibit 146        Gilead Sciences Revenue 2017–2020 ($ billion)

Exhibit 147        Gilead Sciences’ R&D Expenditure 2017–2020 ($ billion)

Exhibit 148        Gilead Sciences Segments Revenue 2018–2020 ($ billion)

Exhibit 149        Gilead Sciences Sales Breakdown by Key Counties & Region 2108–2020 ($ billion)

Exhibit 150        Amgen Revenue during 2018–2020 (million)

Exhibit 151        Amgen’s R&D Expenditure 2018–2020 ($ million)

Exhibit 152        Organogenesis Revenue 2017–2020 ($ million)

Exhibit 153        Bristol-Myers Squibb Revenue 2018–2020 ($ million)

Exhibit 154        Bristol-Myers Squibb’s R&D Expenditure 2018–2020 ($ million)

Exhibit 155        Vericel Revenue during 2018–2020 ($ million)

Exhibit 156        Product-wise Revenues of Vericel in 2018-2020 ($ million)

Exhibit 157        Osiris Revenue 2017–2019 ($ million)

Exhibit 158        Osiris Sales & Marketing Expenditure 2017–2018 ($ million)

Exhibit 159        Product-wise Revenues of Osiris Therapeutics 2017–2018 ($ million)

             

             

             

                           

List of Tables    

Table 1               Key Caveats

Table 2               Currency Conversion 2013−2020

Table 3               Additive Manufacturing Techniques for Scaffolds Fabrication

Table 4               Pipeline products in Regenerative medicine

Table 5               Regenerative Medicine Products under RMAT Designation

Table 6               Regenerative Medicines under PRIME Designation

Table 7               Regenerative Medicines under SAKIGAKE Designation

Table 8               Major M&A in Regenerative Medicine Market between 2014 & 2016

Table 9               Recent Acquisitions in Global Regenerative Medicine Market

Table 10             CAR T-Cell Investigational Products

Table 11             Guidance and Key Features by US FDA Regulatory Framework

Table 12             Product Approvals & Launch Details

Table 13             Recent Regenerative Medicine Products under RMAT Designation 2020–2021

Table 14             Cost of Kymriah in Different Regions

Table 15             Major Vendors offering Regenerative Products in Dermatology

Table 16             Pipeline Products of Key Vendors in Musculoskeletal Application

Table 17             Major Vendors offering Regenerative Products in Musculoskeletal Application

Table 18             Expedited Product Approvals in Oncology in 2020

Table 19             Major Vendors offering Regenerative Products in Oncology Application

Table 20             Expedited Product Approvals for Genetic Disorders in 2020

Table 21             Major Vendors offering Regenerative Products for Genetic Disorders

Table 22             Significant Players offering Regenerative Products for Other Diseases

Table 23             Key Players offering Gene Therapy Products for Several Indications

Table 24             Key Players offering Cell Therapy Products for Several Indications

Table 25             Key Vendors offering Products in Tissue-engineering Products

Table 26             List of Gene Therapy Areas Active Research Institutes in US and Canada

Table 27             Recent US FDA approved Regenerative Medicines including Cell and Gene Therapies

Table 28             Recent Regenerative Medicine Products approved by Health Canada

Table 29             Recent ATMP’s approved in Europe by European Medicines Agency

Table 30             Recent Products under SAKIGAKE Designation

Table 31             Recent Regenerative Product Approvals in Japan

Table 32             Regenerative Medicine Products approved in South Korea

Table 33             Key Competitive Factors in Global Regenerative Medicine Market

Table 34             Global Regenerative Medicine Market: Vendors Ranking

Table 35             Global Gene Therapy Market: Vendors Ranking

Table 36             Global Cell Therapy Market: Vendors Ranking

Table 37             Global Tissue-Engineered Products Market: Vendors Ranking

Table 38             Novartis: Major Product Offerings

Table 39             Gilead Sciences: Major Product Offerings

Table 40             Amgen: Major Product Offerings

Table 41             Organogenesis:  Product Offerings

Table 42             Bristol Myers Squibb:  Product Offerings

Table 43             Vericel:  Product Offerings

Table 44             Osiris Therapeutics: Product Offerings

Table 45             Anges: Major Product Offerings

Table 46             APAC Biotech: Major Product Offerings

Table 47             Avita Medical: Major Product Offerings

Table 48             Bio Solution: Major Product Offerings

Table 49             bluebird bio: Major Product Offerings

Table 50             CHIESI FARMACEUTICI: Major Product Offerings

Table 51             CO.DON: Major Product Offerings

Table 52             COLLPLANT: Major Product Offerings

Table 53             CoreStem: Major Product Offerings

Table 54             GC Pharma: Major Product Offerings

Table 55             Human Stem Cell Institute: Major Product Offerings

Table 56             Integra Life sciences: Major Product Offerings

Table 57             JCR Pharmaceutical: Major Product Offerings

Table 58             J-TEC: Major Product Offerings

Table 59             JW CreaGene: Major Product Offerings

Table 60             Medipost: Major Product Offerings

Table 61             MiMedx: Major Product Offerings

Table 62             Misonix: Major Product Offerings

Table 63             Mesoblast: Major Product Offerings in its Pipeline

Table 64             Nipro: Major Product Offerings

Table 65             NuVasive: Major Product Offerings

Table 66             Orchard Therapeutics: Major Product Offerings

Table 67             Orthofix: Major Product Offerings

Table 68             Orthocell: Major Product Offerings

Table 69             S-BIOMEDICS: Major Product Offerings

Table 70             Sibiono GeneTech: Major Product Offerings

Table 71             Shanghai Sunway Biotech: Major Product Offerings

Table 72             Stempeutics: Major Product Offerings

Table 73             Takeda Pharmaceuticals: Major Product Offerings

Table 74             Tego Science: Major Product Offerings

Table 75             Terumo: Major Product Offerings

Table 76             TissueTech: Major Product Offerings

Table 77             Global Regenerative Medicine Market by Geography 2020–2026($ million)

Table 78             Global Regenerative Medicine Market by Geography 2020–2026(%)

Table 79             Global Regenerative Medicine Market by Application 2020−2026 ($ million)

Table 80             Global Regenerative Medicine Market by Application 2020−2026 (%)

Table 81             Global Regenerative Medicine Market by Product 2020–2026($ million)

Table 82             Global Regenerative Medicine Market by Product 2020–2026 (%)

Table 83             Global Regenerative Medicine Market by End-user 2020–2026($ million)

Table 84             Global Regenerative Medicine Market by End-users 2020–2026(%)

Select a license type that suits your business needs

Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date